Johnson & Johnson: acquires V-Wave
(CercleFinance.com) - Johnson & Johnson announces that it has entered into a definitive agreement to acquire V-Wave Ltd, an unlisted company focused on the development of innovative treatment options for heart failure patients.
The healthcare group will make an upfront payment of $600m, subject to customary adjustments, with the possibility of additional regulatory and commercial milestone payments of up to approximately $1.1bn.
This acquisition should strengthen Johnson & Johnson MedTech's position in the treatment of cardiovascular disease, and further accelerate its transformation into high-growth, high-opportunity markets.
The transaction is expected to close before the end of 2024, subject to regulatory approvals and other customary conditions. Johnson & Johnson expects this to have a dilutive effect on its adjusted EPS of around $0.24 in 2024, tapering off to around $0.06 in 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The healthcare group will make an upfront payment of $600m, subject to customary adjustments, with the possibility of additional regulatory and commercial milestone payments of up to approximately $1.1bn.
This acquisition should strengthen Johnson & Johnson MedTech's position in the treatment of cardiovascular disease, and further accelerate its transformation into high-growth, high-opportunity markets.
The transaction is expected to close before the end of 2024, subject to regulatory approvals and other customary conditions. Johnson & Johnson expects this to have a dilutive effect on its adjusted EPS of around $0.24 in 2024, tapering off to around $0.06 in 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.